BioPharma Credit PLC (LON:BPCR)
London · Delayed Price · Currency is GBP · Price in USD 0.9760
+0.0060 (0.62%)
Oct 15, 2026, 2:12 PM GMT
BioPharma Credit Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 68.71 | 12.59 | 5.62 | 135.05 | 120.53 | 94.71 |
Cash & Short-Term Investments | 68.71 | 12.59 | 5.62 | 135.05 | 120.53 | 94.71 |
Cash Growth | 1496.05% | 123.97% | -95.84% | 12.05% | 27.26% | -51.00% |
Accounts Receivable | 15.05 | 53.46 | 31.71 | 20.23 | 19.73 | 9.59 |
Other Receivables | 1.67 | 0.14 | 0.08 | 0.09 | 0.11 | 0.42 |
Receivables | 16.71 | 53.6 | 31.8 | 20.32 | 19.84 | 10.01 |
Total Current Assets | 85.42 | 66.19 | 37.42 | 155.37 | 140.37 | 104.72 |
Long-Term Investments | 1,057 | 1,102 | 1,162 | 1,201 | 1,224 | 1,266 |
Total Assets | 1,142 | 1,168 | 1,200 | 1,357 | 1,364 | 1,371 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | 3.23 | 17.56 | 16.94 | 15.87 | 24.35 | 6.34 |
Other Current Liabilities | - | - | 0.95 | - | 1.95 | - |
Total Current Liabilities | 3.23 | 17.56 | 17.88 | 15.87 | 26.3 | 6.34 |
Long-Term Unearned Revenue | - | - | 0.06 | - | 0.26 | 0.56 |
Total Liabilities | 3.23 | 17.56 | 17.94 | 15.87 | 26.56 | 6.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 |
Additional Paid-In Capital | 607.13 | 607.13 | 607.13 | 607.13 | 607.13 | 607.13 |
Retained Earnings | 517.94 | 530 | 560.81 | 720 | 716.59 | 742.85 |
Shareholders' Equity | 1,139 | 1,151 | 1,182 | 1,341 | 1,337 | 1,364 |
Total Liabilities & Equity | 1,142 | 1,168 | 1,200 | 1,357 | 1,364 | 1,371 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 68.71 | 12.59 | 5.62 | 135.05 | 120.53 | 94.71 |
Net Cash Growth | 1496.05% | 123.97% | -95.84% | 12.05% | 27.26% | -51.00% |
Net Cash Per Share | 0.06 | 0.01 | 0.00 | 0.10 | 0.09 | 0.07 |
Filing Date Shares Outstanding | 1,122 | 1,129 | 1,140 | 1,254 | 1,319 | 1,374 |
Total Common Shares Outstanding | 1,122 | 1,129 | 1,186 | 1,303 | 1,319 | 1,374 |
Working Capital | 82.19 | 48.63 | 19.53 | 139.5 | 114.06 | 98.38 |
Book Value Per Share | 1.01 | 1.02 | 1.00 | 1.03 | 1.01 | 0.99 |
Tangible Book Value | 1,139 | 1,151 | 1,182 | 1,341 | 1,337 | 1,364 |
Tangible Book Value Per Share | 1.01 | 1.02 | 1.00 | 1.03 | 1.01 | 0.99 |